Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Healthcare Biotechnology
Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Lattice Biologics Ltd > Patients Treated; RAPID KNOWN RESULTS (Frm: China study)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(26)
•••
Comment by colimaon Mar 19, 2020 9:47pm
60 Views
Post# 30828927

RE:RE:RE:Patients Treated; RAPID KNOWN RESULTS (Frm: China study)

RE:RE:RE:Patients Treated; RAPID KNOWN RESULTS (Frm: China study)To read the full study:. Leng Z, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and Disease, 10.14336/AD.2020.0228
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities